Additionally, CTC evaluation of mice with PDX tumors with obASCs demonstrated a trend of an increased percentage of human cells enriched for the cancer stem cell marker CD44+CD24− compared to mice with control tumors and tumors with shLeptin obASCs (Fig. 5c). This evidence concerns the gene CD44 and cancer.